Transthyretin Mimetics as Anti‐β‐Amyloid Agents: A Comparison of Peptide and Protein Approaches

ChemMedChem - Tập 13 Số 9 - Trang 968-979 - 2018
Kayla M. Pate1, Brandon J. Kim1, Eric V. Shusta1, Regina M. Murphy1
1Department of Chemical and Biological Engineering University of Wisconsin – Madison 1415 Engineering Drive Madison WI 53706 USA

Tóm tắt

Abstractβ‐Amyloid (Aβ) aggregation is causally linked to neuronal pathology in Alzheimer's disease; therefore, several small molecules, antibodies, and peptides have been tested as anti‐Aβ agents. We developed two compounds based on the Aβ‐binding domain of transthyretin (TTR): a cyclic peptide cG8 and an engineered protein mTTR, and compared them for therapeutically relevant properties. Both mTTR and cG8 inhibit fibrillogenesis of Aβ, with mTTR inhibiting at a lower concentration than cG8. Both inhibit aggregation of amylin but not of α‐synuclein. They both bind more Aβ aggregates than monomer, and neither disaggregates preformed fibrils. cG8 retained more of its activity in the presence of biological materials and was more resistant to proteolysis than mTTR. We examined the effect of mTTR or cG8 on Aβ binding to human neurons. When mTTR was co‐incubated with Aβ under oligomer‐forming conditions, Aβ morphology was drastically changed and Aβ‐cell deposition significantly decreased. In contrast, cG8 did not affect morphology but decreased the amount of Aβ deposited. These results provide guidance for further evolution of TTR‐mimetic anti‐amyloid agents.

Từ khóa


Tài liệu tham khảo

Alzheimer's Association Alzheimer′s Dementia2016 12 459–509.

 

10.1152/physrev.00042.2009

10.1006/jsbi.2000.4262

 

10.1016/j.bmc.2015.02.041

10.1016/j.ejmech.2016.02.049

10.1038/aps.2011.14

Doig A. J., 2007, Curr. Opin. Drug Discovery Dev., 10, 533

10.1517/14712598.2014.935332

10.1002/cmdc.200700140

10.1039/C5CC05264E

10.1021/acschemneuro.6b00175

 

10.1111/j.1365-2125.2011.04134.x

10.1002/cmdc.201500215

10.1021/acscombsci.6b00116

10.1111/cbdd.12055

 

10.3389/fnagi.2014.00114

10.1056/NEJMoa1312889

10.1186/s13195-016-0189-7

10.1038/nature19323

 

10.1021/bi982119e

10.1021/ar8000475

10.1021/ja0619861

 

10.1021/bi0618520

10.1093/protein/gzs026

10.1016/j.neurobiolaging.2006.04.009

10.1523/JNEUROSCI.2211-04.2004

10.1523/JNEUROSCI.22-17-07380.2002

10.1073/pnas.0712197105

 

10.1016/j.clinbiochem.2005.08.007

10.1016/j.febslet.2008.02.034

10.1523/JNEUROSCI.2417-11.2011

10.1021/bi4001613

10.1523/JNEUROSCI.5901-11.2012

 

10.1523/JNEUROSCI.2561-13.2013

10.1021/bi101280t

10.1021/cn500014u

10.1021/cn500272a

10.1021/acschemneuro.6b00150

10.1021/bi011194d

 

10.1021/bi0001980

10.1074/jbc.M111.329763

R. M.Murphy P. Y.Cho J. A.Johnson X.Lu(University of Wisconsin – Madison) US Pat. No. US9809627 2015.

10.1016/j.bbapap.2010.04.001

10.1016/S0168-9525(00)02024-2

10.1016/j.stem.2017.04.002

10.1111/jnc.13923

 

10.1021/bi8002378

10.1038/nsmb.1437

10.1074/jbc.M608207200

10.1021/bi0600749

10.1021/bi901285x

10.1016/j.bcp.2013.12.023

10.1016/j.jmb.2016.03.013

10.1126/science.1079469

10.2478/s13380-013-0137-y

Schwarzman A. L., The Nature and Origin of Amyloid Fibrils, 146

 

10.1371/journal.pone.0100519

10.1016/S0022-2275(20)31605-9

10.1097/00002093-199809000-00012

10.1002/anie.200904902

10.1002/ange.200904902

Thông tin
Thông tin xuất bản

ChemMedChem

Tập 13 Số 9

968-979

Thông tin tác giả